ProPhase Labs (NASDAQ:PRPH) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a report released on Thursday. The brokerage set a “sell” rating on the stock.

ProPhase Labs Stock Performance

Shares of NASDAQ:PRPH traded down $0.02 during midday trading on Thursday, reaching $0.49. 338,862 shares of the company traded hands, compared to its average volume of 438,242. The firm’s fifty day moving average price is $0.69 and its two-hundred day moving average price is $1.89. The firm has a market capitalization of $11.70 million, a price-to-earnings ratio of -0.39 and a beta of -0.30. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. ProPhase Labs has a 12 month low of $0.46 and a 12 month high of $7.48.

Hedge Funds Weigh In On ProPhase Labs

A number of institutional investors have recently added to or reduced their stakes in the business. Sheets Smith Wealth Management purchased a new position in shares of ProPhase Labs in the 4th quarter worth about $158,000. HighTower Advisors LLC lifted its position in ProPhase Labs by 18.3% in the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock worth $434,000 after buying an additional 27,673 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in ProPhase Labs by 9.2% in the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock worth $389,000 after buying an additional 13,590 shares in the last quarter. 9.45% of the stock is currently owned by institutional investors.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.